At what gestational age should RhoGAM (Rho(D) immune globulin) be administered to Rh-negative mothers?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: August 15, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

RhoGAM Administration Timing During Pregnancy

RhoGAM should be administered to unsensitized Rh-negative women at 28 weeks' gestation, followed by another dose within 72 hours after delivery if the infant is Rh-positive. 1

Standard Administration Protocol

The recommended timing for RhoGAM administration follows a specific schedule:

  1. Routine Antenatal Prophylaxis:

    • 300 mcg dose at 28 weeks' gestation 1, 2
    • Alternative: Two doses of 100-120 mcg (one at 28 weeks and one at 34 weeks) 3
  2. Postpartum Administration:

    • 300 mcg within 72 hours after delivery of an Rh-positive infant 1, 2
    • If administration is delayed beyond 72 hours, RhoGAM should still be given up to 28 days after delivery 3

Special Circumstances Requiring RhoGAM

RhoGAM should also be administered in the following situations:

  • Early Pregnancy Events (before 12 weeks' gestation):

    • 50 mcg (microdose) is typically adequate 1
    • 300 mcg if microdose is unavailable 1
  • After 12 weeks' gestation:

    • 300 mcg for any potentially sensitizing event 3
  • Specific Events Requiring Administration:

    • Spontaneous or induced abortion
    • Ruptured tubal pregnancy
    • Amniocentesis
    • Abdominal trauma
    • Chorionic villus sampling (120 mcg before 12 weeks, 300 mcg after 12 weeks) 3
    • Cordocentesis (300 mcg) 3

Duration of Protection

The 28-week timing for antenatal prophylaxis is critical as studies show:

  • A single 300 mcg dose at 28 weeks provides protection through delivery in most cases 4
  • However, in some women, detectable antibody levels may not persist until delivery 5
  • A repeat dose is generally not required at 40 weeks if the initial dose was given at 28 weeks 3

Efficacy of Antenatal Administration

Research demonstrates that antenatal RhoGAM administration at 28 weeks:

  • Is 88% effective in preventing Rh isoimmunization during pregnancy in Rh-negative primigravidas 4
  • Reduces the incidence of Rh isoimmunization from approximately 1.6% to less than 0.1% when combined with postpartum administration 2

Common Pitfalls to Avoid

  1. Failing to administer both doses: If RhoGAM is given antepartum, it is essential that the mother receive another dose after delivery of an Rh-positive infant 2

  2. Confusing blood type with antibody status: This can lead to inappropriate RhoGAM administration 1

  3. Administering to Rh-positive women: This is unnecessary and wastes a limited resource 1

  4. Missing the window for maximum effectiveness: While RhoGAM is most effective within 72 hours of delivery or a sensitizing event, it should still be given up to 28 days after if the need is recognized late 3

  5. Not adjusting dosage for large fetomaternal hemorrhage: Additional anti-D may be required for fetomaternal hemorrhage greater than 15 mL of fetal red blood cells 3

The evidence strongly supports that the 28-week gestational age timing for routine antenatal RhoGAM administration, followed by postpartum administration, provides optimal protection against Rh alloimmunization.

References

Guideline

Rh Alloimmunization Prevention in Pregnancy

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Prevention of Rh alloimmunization.

Journal of obstetrics and gynaecology Canada : JOGC = Journal d'obstetrique et gynecologie du Canada : JOGC, 2003

Research

Postinjection kinetics of antepartum Rh immune globulin.

American journal of obstetrics and gynecology, 1990

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.